Marcelo Araujo Queiroz

Marcelo Araujo Queiroz

Auto-generated profile, based on publicly available information

Marcelo Araujo Queiroz

Universidade de São Paulo, Sao Paulo, Brazil

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 March 2020 in Cancer Imaging
Verified
Journal Article
Open access
PDF file
FBFelipe de Galiza Barbosa
Felipe de Galiza Barbosa
MQMarcelo Araujo Queiroz
Marcelo Araujo Queiroz
RNRafael Fernandes Nunes
Rafael Fernandes Nunes
LCLarissa Bastos Costa
Larissa Bastos Costa
EZElaine Caroline Zaniboni
Elaine Caroline Zaniboni
CBCarlos Buchpiguel
Carlos Buchpiguel
PSMA PET imaging was originally used to assess biochemical recurrence of prostate cancer (PCa), but its clinical use was promptly extended to detection, staging and therapy response assessment. The expanding use of PSMA PET worldwide has also revealed PSMA ligand uptake in diverse nonprostatic diseases, which raised questions about the specificity of this imaging modality. Although not very common initially, a growing number of pathologies presenting PSMA uptake on PET have been reported in the last few years, and a proper interpretation of PSMA PET imaging findings suddenly became challenging and, to some extent, confusing. Compared to cytoplasmic PSMA expression in nonprostatic cells, the molecular features of apical PSMA expression in PCa cells can help to distinguish these various conditions. Correlations of imaging findings to patient history, to the expected pattern of disease spread and mainly to computed tomography (CT) and/or magnetic resonance imaging (MRI) characteristics will reinforce the distinction of lesions that are more likely related to PCa from those that could lead to an incorrect diagnosis. The overall benefits of endothelial PSMA expression, which is associated with the neovasculature of malignant neoplasms, will be highlighted, stating the potential use of PSMA ligand uptake as a theranostic tool. This review aims to cover the collection of nonprostatic diseases, including benign and malignant tumors, in a didactic approach according to disease etiology, with discussion of bone-related conditions and inflammatory and infectious processes.

1 October 2020 in RadioGraphics
Verified
Journal Article
Closed access
JMJosé Flávio Gomes Marin
José Flávio Gomes Marin
RNRafael F. Nunes
Rafael F. Nunes
ACArtur M. Coutinho
Artur M. Coutinho
EZElaine C. Zaniboni
Elaine C. Zaniboni
LCLarissa B. Costa
Larissa B. Costa
CBCarlos A. Buchpiguel
Carlos A. Buchpiguel
Theranostics refers to the pairing of diagnostic biomarkers with therapeutic agents that share a specific target in diseased cells or tissues. Nuclear medicine, particularly with regard to applications in oncology, is currently one of the greatest components of the theranostic concept in clinical and research scenarios. Theranostics in nuclear medicine, or nuclear theranostics, refers to the use of radioactive compounds to image biologic phenomena by means of expression of specific disease targets such as cell surface receptors or membrane transporters, and then to use specifically designed agents to deliver ionizing radiation to the tissues that express these targets. The nuclear theranostic approach has sparked increasing interest and gained importance in parallel to the growth in molecular imaging and personalized medicine, helping to provide customized management for various diseases; improving patient selection, prediction of response and toxicity, and determination of prognosis; and avoiding futile and costly diagnostic examinations and treatment of many diseases. The authors provide an overview of theranostic approaches in nuclear medicine, starting with a review of the main concepts and unique features of nuclear theranostics and aided by a retrospective discussion of the progress of theranostic agents since early applications, with illustrative cases emphasizing the imaging features. Advanced concepts regarding the role of fluorine 18-fluorodeoxyglucose PET in theranostics, as well as developments in and future directions of theranostics, are discussed. ©RSNA, 2020 See discussion on this article by Greenspan and Jadvar.

29 May 2015 in European Radiology
Verified
Journal Article
Closed access
PDF file
MQMarcelo A. Queiroz
Marcelo A. Queiroz
RKRahel A. Kubik-Huch
Rahel A. Kubik-Huch
NHNik Hauser
Nik Hauser
BFBianka Freiwald-Chilla
Bianka Freiwald-Chilla
GSGustav von Schulthess
Gustav von Schulthess
PVPatrick Veit-Haibach
Patrick Veit-Haibach

1 January 2019 in RadioGraphics
Verified
Journal Article
Closed access
FBFelipe G. Barbosa
Felipe G. Barbosa
MQMarcelo A. Queiroz
Marcelo A. Queiroz
RNRafael F. Nunes
Rafael F. Nunes
PVPublio C. C. Viana
Publio C. C. Viana
JMJosé Flávio G. Marin
José Flávio G. Marin
CBCarlos Buchpiguel
Carlos Buchpiguel
This article demonstrates the different patterns of dissemination of prostate cancer relapse, presenting the typical sites of disease manifestation and emphasizing the appearance of the increasingly common forms of atypical spread. The authors also correlate the imaging findings with the treatment approaches and the potential clinical impact. The introduction of prostate-specific membrane antigen (PSMA) in clinical practice has revolutionized evaluation of biochemical recurrence of prostate cancer after curative-intent treatment. The high expression of this glycoprotein in prostate cancer cells makes PSMA imaging superior to the current conventional staging methods, namely bone scanning and CT. The high capability of PSMA imaging for identifying very small previously undetected lesions has been widely demonstrated in the literature, leading to a rethinking of patient management by oncologists, urologists, and radiation oncologists. The typical and predictable patterns of spread in prostate cancer are still more prevalent, such as spread to pelvic lymph nodes and bone metastasis, but different patterns of disease spread are becoming more commonly recognized with higher reliability because PSMA imaging allows detection of more typical and atypical lesions than conventional imaging. Furthermore, it is important for the reading physician to recogn...

1 May 2015 in Seminars in Nuclear Medicine
Verified
Journal Article
Closed access
MQMarcelo A. Queiroz
Marcelo A. Queiroz
MHMartin W Huellner
Martin W Huellner

5 August 2014 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
MQMarcelo A. Queiroz
Marcelo A. Queiroz
MHMartin Hüllner
Martin Hüllner
FKFelix Kuhn
Felix Kuhn
GHGerhardt Huber
Gerhardt Huber
CMChristian Meerwein
Christian Meerwein
PVPatrick Veit-Haibach
Patrick Veit-Haibach